HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk : role of protease inhibitor exposure.
HIV, metabolic syndrome X, inflammation, oxidative stress, and coronary heart disease risk : role of protease inhibitor exposure.
复制标题
DOI：
10.1385/ct:4:3:303
复制
发表时间：
2004-01-01
影响因子：
3.2
通讯作者：
Schneiderman, Neil
中科院分区：
文献类型：
--
作者：
Hurwitz, Barry E;Klimas, Nancy G;Schneiderman, Neil
代谢综合征X和冠心病（CHD）的风险，以及潜在的病理生理介质，炎症和氧化应激的措施的差异，作为HIV血清状态和高效抗逆转录病毒治疗（HAART）方案与蛋白酶抑制剂（PI）的功能进行了检查。来自164名年龄在18 - 55岁之间的男性和女性的数据被用来比较82名HIV+受试者，他们没有丙型肝炎病毒并且接受稳定的HAART方案≥ 6个月，82名血清阴性受试者在年龄、性别、体重指数和种族上匹配。对于HIV+受试者，在控制糖尿病状态和HIV疾病进展后，PI暴露与非PI暴露的HIV+受试者相比，与更大的氧化应激、三酸甘油酯血症和脂血症相关，并且未来心肌梗死的风险高达56% PI暴露的受试者比非PI暴露的受试者高，比对照组高129%。尽管HIV+受试者中CHD风险的最大比例可能是由与HIV感染相关的病理学状况与介导过程（如炎症、向心性肥胖和血脂异常）相互作用所致（高于对照组），但PI药物似乎可能加重氧化应激和高脂血症，从而增加该风险。
Differences on measures of metabolic syndrome X and coronary heart disease (CHD) risk, as well as potential pathophysiological mediators, inflammation, and oxidative stress, were examined as a function of HIV serostatus and highly active antiretroviral therapy (HAART) regimen with and without protease inhibitors (PIs). Data from 164 men and women, aged 18 to 55 yr, were used to compare 82 HIV+ subjects who were free of hepatitis C virus and were on a stable HAART regimen for >/=6 mo, with 82 seronegative subjects matched on age, sex, body mass index, and ethnicity. For the HIV+ subjects, after controlling for diabetes status and HIV disease progression, PI exposure was associated with greater oxidative stress, triglyceridemia, and lipidemia than it was for non-PI-exposed HIV+ subjects, and the risk of a future myocardial infarction was up to 56% greater in PI-exposed than in non-PI-exposed subjects and 129% greater than in controls. Although it is likely that the greatest proportion of CHD risk in the HIV+ subjects may be accounted for by pathological conditions linked to HIV infection in interaction with mediating processes such as inflammation, central obesity, and dyslipidemia, which was greater than in controls, it appears that PI medications may exacerbate oxidative stress and hypertriglyceridemia to enhance this risk.